文献速递乳腺癌

88个单核苷酸多态性组合对高危女性乳腺癌风险的影响:来自两项随机他莫昔芬预防试验的结果

Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials.
PubMed 文献 · J Clin Oncol · 2016-12-28

该研究基于国际乳腺干预研究(IBIS-I)和皇家马斯登研究的巢式病例对照设计,评估88个单核苷酸多态性(SNP88)风险评分在高危女性中的表现。结果显示SNP88整体可预测乳腺癌风险(四分位距比值比1.37),主要见于雌激素受体阳性疾病,且与Tyrer-Cuzick模型独立,联合后可改善预测(四分位距比值比1.64,匹配一致性指数0.60)。作者认为多基因风险评分可用于优化他莫昔芬预防治疗决策中的风险分层,但可能需要重新校准。

要点

  • SNP88整体预测乳腺癌风险(四分位距比值比1.37,95%CI 1.14-1.66),主要见于雌激素受体阳性疾病。
  • SNP88与Tyrer-Cuzick模型独立,联合后预测能力提升(四分位距比值比1.64,匹配一致性指数0.60)。
  • SNP88与他莫昔芬治疗无显著交互作用(异质性P=0.5),但观察风险仅为预期的46%。

核心结论

  • 多基因风险评分或可用于优化Tyrer-Cuzick等模型对高危且考虑预防治疗女性的风险分层,但准确风险评估可能需要重新校准。

研究设计与样本

  • 巢式病例对照研究,纳入国际乳腺干预研究(IBIS-I)或皇家马斯登研究的女性,359例乳腺癌患者按年龄、试验、随访时间和治疗组与636例对照匹配,使用OncoArray进行基因分型。

主要发现

  • SNP88整体预测乳腺癌风险(四分位距比值比1.37,95%CI 1.14-1.66,匹配一致性指数0.55),主要见于雌激素受体阳性疾病(四分位距比值比1.44,95%CI 1.16-1.79,异质性P=0.10)。
  • SNP88观察风险仅为预期的46%(95%CI 19%-74%)。
  • SNP88与治疗组无显著交互作用(安慰剂组四分位距比值比1.46,95%CI 1.13-1.87;他莫昔芬组四分位距比值比1.25,95%CI 0.96-1.64;异质性P=0.5)。
  • SNP88预测能力与Tyrer-Cuzick模型相似(四分位距比值比1.45,95%CI 1.21-1.73,匹配一致性指数0.55),但两者独立(Spearman秩相关0.012,P=0.7)。
  • SNP88与Tyrer-Cuzick模型乘法联合后预测能力显著改善(四分位距比值比1.64,95%CI 1.36-1.97,匹配一致性指数0.60)。

临床怎么用

  • 作者认为,多基因风险评分或可用于优化Tyrer-Cuzick或类似模型对高危且考虑预防治疗女性的风险分层。
  • 作者指出,准确风险评估可能需要重新校准。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose At least 94 common single nucleotide polymorphisms (SNPs) are associated with breast cancer. The extent to which an SNP panel can refine risk in women who receive preventive therapy has not been directly assessed previously. Materials and Methods A risk score on the basis of 88 SNPs (SNP88) was investigated in a nested case-control study of women enrolled in the International Breast Intervention Study (IBIS-I) or the Royal Marsden study. A total of 359 women who developed cancer were matched to 636 controls by age, trial, follow-up time, and treatment arm. Genotyping was done using the OncoArray. Conditional logistic regression and matched concordance indices (mC) were used to measure the performance of SNP88 alone and with other breast cancer risk factors assessed using the Tyrer-Cuzick (TC) model. Results SNP88 was predictive of breast cancer risk overall (interquartile range odds ratio [IQ-OR], 1.37; 95% CI, 1.14 to 1.66; mC, 0.55), but mainly for estrogen receptor-positive disease (IQ-OR, 1.44; 95% CI, 1.16 to 1.79; P for heterogeneity = .10) versus estrogen receptor-negative disease. However, the observed risk of SNP88 was only 46% (95% CI, 19% to 74%) of expected. No significant interaction was observed with treatment arm (placebo IQ-OR, 1.46; 95% CI, 1.13 to 1.87; tamoxifen IQ-OR, 1.25; 95% CI, 0.96 to 1.64; P for heterogeneity = .5). The predictive power was similar to the TC model (IQ-OR, 1.45; 95% CI, 1.21 to 1.73; mC, 0.55), but SNP88 was independent of TC (Spearman rank-order correlation, 0.012; P = .7), and when combined multiplicatively, a substantial improvement was seen (IQ-OR, 1.64; 95% CI, 1.36 to 1.97; mC, 0.60). Conclusion A polygenic risk score may be used to refine risk from the TC or similar models in women who are at an elevated risk of breast cancer and considering preventive therapy. Recalibration may be necessary for accurate risk assessment.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Cuzick J, Brentnall AR, Segal C, et al. Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials. J Clin Oncol. 2016. PMID: 28029312. doi:10.1200/JCO.2016.69.8944

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。